Previous Close | 5.25 |
Open | 5.42 |
Bid | 5.24 x 1000 |
Ask | 7.08 x 1200 |
Day's Range | 5.25 - 5.79 |
52 Week Range | 5.00 - 14.16 |
Volume | |
Avg. Volume | 3,645 |
Market Cap | 49.045M |
Beta (5Y Monthly) | 0.58 |
PE Ratio (TTM) | 11.98 |
EPS (TTM) | 0.48 |
Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
OLDSMAR, Fla., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (“Cryo-Cell”, the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that it will change its listing from the Nasdaq Capital Market to the NYSE American stock exchange on August 30, 2022. David Portnoy, Chairman and Co-CEO of Cryo-Cell, said, “The New York Stock Exchange has been trading stocks for over 225 years and is
OLDSMAR, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2022. Financial Results Revenue Consolidated revenues for the second quarter of fiscal 2022 were $7.63 million compared to $7.21 million for the second quarter of fiscal 2021, a 6% increase. The revenues for the second
OLDSMAR, Fla., April 13, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2022. Financial Results Revenue The revenues for the first quarter of fiscal 2022 were $7.26 million compared to $6.86 million for the first quarter of fiscal 2021. The revenues for the first quarter of fiscal 2022 co